Sleutel1

Genmab has its stock recommendation lowered to neutral by JPMorgan20/8 06:54Genmab has had its share recommendation lowered by financial house JPMorgan to neutral from &quo...

JPMs 10% downgrade may be a result of the gradual weakening of the USD, which most expect to continue in line with the interest rate cuts. This will affect Genmabs share price negatively in ...

Another one … BTIG analyst Kaveri Pohlman raised the price target on Genmab A/S (NASDAQ: GMAB) to $47.00 (from $46.00) while maintaining a Buy rating...

Fyi … UBS Remains a Buy on Genmab A/S Jun. 26, 2024, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,750.00....

Hai Irene, weet je ook in welke size Genmab Board Member Anders Peters zijn holding heeft teruggebracht … uit persbericht van 11 juni blijkt dat hij maar slechts 2.000 aandelen heeft verkocht op gem....

Xian Deng from UBS: Genmab Buy DKK 2,750.00 Maintained Today...

From Nordeas morning commentary: Genmab (team) - Over the weekend, at the ASCO24 conference in Chicago, Genmab and BioNTech presented updated phase II data for acasunlimab (GEN1046), a PD-L1x4-1B...

DNB lowers PT Genmab from DKK 2,630 to DKK 2,600 Buy...

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-smal...

Beste Highlands, zou je deze ook met ons kunnen delen. Alvast bedankt!...